Global Underactive Bladder Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143203
- Pages: 225
-
Format:
Short Description
Global Underactive Bladder Market, By Treatment (Pharmacotherapy, Surgical Methods, Urethral Assist Device, and Stem Cell and Gene Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Clinics, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), Country (U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition
Underactive Bladder (UAB) is a clinical condition in which urination disorder is developed as a result of reduction in the contraction of detrusor muscle (a muscle of the bladder) during urination. It is characterized by the feeling of having to urinate immediately, and thus, this condition is different from an Overactive Bladder (OAB). The present invention provides a pharmaceutical composition useful for the prevention or treatment of UAB which has an effect of improving the urinary flow rate, an effect of improving the overdistension of the bladder (an effect of reducing bladder capacity), and is, therefore, useful for the prevention or treatment of UAB.
Moreover, it is a disease state which is different from OAB characterized by urinary urgency which has been attracting attention in recent years. Causes of UAB include autonomic neuropathy such as diabetes and alcoholism, pelvic surgery such as radical hysterectomy and radical rectal cancer, spinal cord diseases such as spina bifida, and disc herniation is also known. The market is driven by the factors such as the rising incidences of prevalence of neurogenic bladder infections, increasing research funding, development of novel therapies for UAB, and pipeline products enhancing its demand as well as rising investment in R&D leads to the market growth. Additionally, the surge in healthcare expenditure and increase in the prevalence of bladder disorders positively affect the market. However, the high cost of treatment restricts patients to accommodate high-quality and effective solutions.
Market Segmentation
Global underactive bladder market is categorized based on treatment, route of administration, end user, and distribution channel.
Based on treatment, the market is segmented into pharmacotherapy, surgical methods, urethral assist device, and stem cell and gene therapies
Based on route of administration, the market is segmented into oral, parenteral, and others
Based on end user, the market is segmented into hospitals, clinics, academic and research institutes, and others
On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and others
Market Players
The key market players operating in the global underactive bladder market are listed below:
Astellas Pharma Inc.
Aurobindo Pharma.
Boehringer Ingelheim International GmbH
Macleods Pharmaceuticals Ltd.
Orion Corporation
ONO PHARMACEUTICAL CO., LTD.
Novartis AG
Pfizer Inc.
Cipla Inc.
Dr. Reddys Laboratories Ltd.
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Almirall, S.A
Glenwood
Vesiflo, Inc.
Alkem Labs.
TABLE OF CONTENTS
1 INTRODUCTION 47
1.1 OBJECTIVES OF THE STUDY 47
1.2 MARKET DEFINITION 47
1.3 OVERVIEW OF THE GLOBAL UNDERACTIVE BLADDER MARKET 47
1.4 LIMITATIONS 49
1.5 MARKETS COVERED 49
2 MARKET SEGMENTATION 52
2.1 MARKETS COVERED 52
2.2 GEOGRAPHICAL SCOPE 53
2.3 YEARS CONSIDERED FOR THE STUDY 54
2.4 CURRENCY AND PRICING 54
2.5 DBMR TRIPOD DATA VALIDATION MODEL 55
2.6 MULTIVARIATE MODELLING 58
2.7 PRODUCT SEGMENT LIFELINE CURVE 58
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 59
2.9 DBMR MARKET POSITION GRID 60
2.10 MARKET APPLICATION COVERAGE GRID 61
2.11 VENDOR SHARE ANALYSIS 62
2.12 SECONDARY SOURCES 63
2.13 ASSUMPTIONS 63
3 EXECUTIVE SUMMARY 64
4 PREMIUM INSIGHTS 68
4.1 PESTEL ANALYSIS 70
4.2 PORTERS FIVE FORCES 71
4.3 EPIDEMIOLOGY 72
4.4 THE IMPORTANCE OF UNDERSTANDING PATENTS- 74
4.4.1 DOXAZOSIN 74
4.4.2 BETHANECHOL CHLORIDE 81
4.4.3 TAMSULOSIN HYDROCHLORIDE 89
4.5 CLINICAL TRIALS FOR UNDERACTIVE BLADDER 91
4.5.1 EU CLINICAL TRIALS REGISTER- 100
4.6 MERGER & ACQUISITION IN HEALTHCARE INDUSTRY 103
4.7 M&A DEALS IN 2021 BY TARGET COMPANY TERRITORY: 105
4.8 CROSS-BORDER DEALS: 106
4.9 OUTLOOK FOR 2022: 106
4.10 PATIENT ENROLMENT STRATEGIES 107
4.11 FACTORS AFFECTING PATIENT RECRUITMENT: 108
4.12 CHALLENGES: 108
4.13 PATIENT FUNNEL ANALYSIS: 108
4.14 RECOMMENDATIONS 109
4.14.1 USE OF TECHNOLOGY: 109
4.14.2 PARTICIPANT CHARACTERISTICS: 109
4.14.3 RECRUITER CHARACTERISTICS: 109
4.14.4 SYSTEMS & PROCEDURES: 109
4.14.5 LOCATION: 110
4.14.6 NATURE OF RESEARCH: 110
4.15 CONCLUSION: 110
4.16 UNDERACTIVE BLADDER PATIENT FLOW DIAGRAM 111
4.17 WHAT CAUSES UNDERACTIVE BLADDER 111
4.17.1 CAUSES OF UNDERACTIVE BLADDER INCLUDE 111
4.17.2 TESTS TO EVALUATE UNDERACTIVE BLADDER 111
4.18 UNDERACTIVE BLADDER INVESTIGATIONAL PRODUCTS- 112
5 GLOBAL UNDERACTIVE BLADDER MARKET: REGULATIONS 115
6 MARKET OVERVIEW 117
6.1 DRIVERS 119
6.1.1 INCREASING PREVALENCE OF NEUROGENIC DISORDER 119
6.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF UNDERACTIVE BLADDER TREATMENT 119
6.1.3 FAVOURABLE REIMBURSEMENT SCENARIO 120
6.1.4 RISING HEALTHCARE EXPENDITURE 120
6.2 RESTRAINTS 121
6.2.1 HIGH COST OF RESEARCH AND DEVELOPMENT 121
6.2.2 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL 121
6.3 OPPORTUNITIES 122
6.3.1 RISING UROLOGIC COMPLICATIONS OF DIABETES 122
6.3.2 PRESENCE OF NOVEL PIPELINE DRUGS 123
6.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM 123
6.4 CHALLENGES 123
6.4.1 LACK OF PROPER TREATMENT 123
6.4.2 RISK INVOLVED DURING TREATMENT OF UNDERACTIVE BLADDER 124
7 GLOBAL UNDERACTIVE BLADDER MARKET, BY TYPE 125
7.1 OVERVIEW 126
7.2 PHARMACOTHERAPY 129
7.2.1 ALPHA-BLOCKERS 130
7.2.2 MUSCARINIC AGONISTS 130
7.2.3 CHOLINESTERASE INHIBITOR 130
7.2.3.1 BY DRUGS 130
7.2.3.1.1 TAMSULOSIN 131
7.2.3.1.2 DOXAZOSIN 131
7.2.3.1.3 DISTIGMINE 131
7.2.3.1.4 BETHANECHOL 131
7.2.3.1.5 OTHERS 131
7.2.4 BY PRODUCT TYPES 131
7.2.4.1 GENERICS 132
7.2.4.2 BRANDED 132
7.2.4.2.1 FLOMAX 132
7.2.4.2.2 ALFADIL 132
7.2.4.2.3 GRAVITOR 132
7.2.4.2.4 URIVOID 132
7.2.4.2.5 OTHERS 132
7.3 SURGICAL METHODS 133
7.3.1 SURGICAL NERVE STIMULATION 134
7.3.2 REDUCTION CYSTOPLASTY 134
7.3.3 SURGERIES FOR BLADDER OBSTRUCTION 134
7.3.4 INJECTION INTO EXTERNAL SPHINCTER 134
7.3.5 OTHERS 134
7.4 URETHRAL ASSIS DEVICE 135
7.4.1 INFLOW INTRAURETHRAL VALVE PUMP 136
7.5 STEM CELL AND GENE THERAPIES 137
7.5.1 NERVE GROWTH FACTOR 139
7.5.2 GLIAL-CELL DERIVE NEUTOPHIC FACTORGLIAL 139
7.5.3 NEUTOPHIN-3 DERIVES FROM GLIALL CELLS 139
8 GLOBAL UNDERACTIVE BLADDER MARKET,BY ROUTE OF ADMINISTRATION 140
8.1 OVERVIEW 141
8.2 PARENTERAL 144
8.3 ORAL 144
8.4 OTHERS 146
9 GLOBAL UNDERACTIVE BLADDER MARKET , BY END USER 147
9.1 OVERVIEW 148
9.2 HOSPITALS 151
9.3 CLINICS 151
9.4 ACADEMIC AND RESEARCH 153
9.5 OTHERS 153
10 GLOBAL UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL 155
10.1 OVERVIEW 156
10.2 HOSPITAL PHARMACY 159
10.3 RETAIL PHARMACY 159
10.4 OTHERS 161
11 GLOBAL UNDERACTIVE BLADDER MARKET, BY REGION 162
11.1 OVERVIEW 163
11.2 NORTH AMERICA 168
11.2.1 U.S. 177
11.2.2 CANADA 181
11.2.3 MEXICO 186
11.3 EUROPE 190
11.3.1 GERMANY 199
11.3.2 FRANCE 203
11.3.3 U.K. 207
11.3.4 ITALY 211
11.3.5 RUSSIA 216
11.3.6 SPAIN 220
11.3.7 TURKEY 224
11.3.8 NETHERLANDS 228
11.3.9 SWITZERLAND 233
11.3.10 POLAND 238
11.3.11 AUSTRIA 242
11.3.12 HUNGARY 246
11.3.13 NORWAY 250
11.3.14 IRELAND 254
11.3.15 LITHUANIA 258
11.3.16 REST OF EUROPE 263
11.4 ASIA-PACIFIC 264
11.4.1 CHINA 273
11.4.2 JAPAN 277
11.4.3 INDIA 281
11.4.4 SOUTH KOREA 285
11.4.5 AUSTRALIA 289
11.4.6 SINGAPORE 293
11.4.7 THAILAND 297
11.4.8 INDONESIA 301
11.4.9 PHILIPPINES 305
11.4.10 MALAYSIA 309
11.4.11 VIETNAM 313
11.4.12 REST OF ASIA-PACIFIC 317
11.5 SOUTH AMERICA 318
11.5.1 BRAZIL 327
11.5.2 ARGENTINA 331
11.5.3 PERU 335
11.5.4 REST OF SOUTH AMERICA 339
11.6 MIDDLE EAST AND AFRICA 340
11.6.1 SOUTH AFRICA 349
11.6.2 SAUDI ARABIA 353
11.6.3 U.A.E 357
11.6.4 ISRAEL 361
11.6.5 EGYPT 365
11.6.6 KUWAIT 369
11.6.7 REST OF MIDDLE EAST AND AFRICA 373
12 GLOBAL UNDERACTIVE BLADDER MARKET: COMPANY LANDSCAPE 374
12.1 COMPANY SHARE ANALYSIS: GLOBAL 374
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 375
12.3 COMPANY SHARE ANALYSIS: EUROPE 376
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 377
13 SWOT ANALYSIS 378
14 COMPANY PROFILES 379
14.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 379
14.1.1 COMPANY SNAPSHOT 379
14.1.2 COMPANY SHARE ANALYSIS 379
14.1.3 PRODUCT PORTFOLIO 380
14.1.4 RECENT DEVELOPMENT 380
14.2 PFIZER INC. 381
14.2.1 COMPANY SNAPSHOT 381
14.2.2 REVENUE ANALYSIS 381
14.2.3 COMPANY SHARE ANALYSIS 382
14.2.4 PRODUCT PORTFOLIO 382
14.2.5 RECENT DEVELOPMENT 382
14.3 SUN PHARMACEUTICAL INDUSTRIES LTD. 383
14.3.1 COMPANY SNAPSHOT 383
14.3.2 REVENUE ANALYSIS 383
14.3.3 COMPANY SHARE ANALYSIS 384
14.3.4 PRODUCT PORTFOLIO 384
14.3.5 RECENT DEVELOPMENT 384
14.4 TEVA PHARMACEUTICAL INDUSTRIES LTD 385
14.4.1 COMPANY SNAPSHOT 385
14.4.2 REVENUE ANALYSIS 385
14.4.3 COMPANY SHARE ANALYSIS 386
14.4.4 PRODUCT PORTFOLIO 386
14.4.5 RECENT DEVELOPMENT 386
14.5 NOVARTIS AG 387
14.5.1 COMPANY SNAPSHOT 387
14.5.2 REVENUE ANALYSIS 387
14.5.3 COMPANY SHARE ANALYSIS 388
14.5.4 PRODUCT PORTFOLIO 388
14.5.5 RECENT DEVELOPMENT 388
14.6 DR. REDDYS LABORATORIES LTD. 389
14.6.1 COMPANY SNAPSHOT 389
14.6.2 REVENUE ANALYSIS 389
14.6.3 PRODUCT PORTFOLIO 390
14.6.4 RECENT DEVELOPMENT 390
14.7 ASTELLAS PHARMA INC. 391
14.7.1 COMPANY SNAPSHOT 391
14.7.2 REVENUE ANALYSIS 391
14.7.3 PRODUCT PORTFOLIO 392
14.7.4 RECENT DEVELOPMENT 392
14.8 ORION CORPORATION. 393
14.8.1 COMPANY SNAPSHOT 393
14.8.2 REVENUE ANALYSIS 393
14.8.3 PRODUCT PORTFOLIO 394
14.8.4 RECENT DEVELOPMENT 394
14.9 ALKEM LABS. 395
14.9.1 COMPANY SNAPSHOT 395
14.9.2 REVENUE ANALYSIS 395
14.9.3 PRODUCT PORTFOLIO 396
14.9.4 RECENT DEVELOPMENT 396
14.10 ALMIRALL, S.A 397
14.10.1 COMPANY SNAPSHOT 397
14.10.2 REVENUE ANALYSIS 397
14.10.3 PRODUCT PORTFOLIO 398
14.10.4 RECENT DEVELOPMENT 398
14.11 AUROBINDO PHARMA. 399
14.11.1 COMPANY SNAPSHOT 399
14.11.2 REVENUE ANALYSIS 399
14.11.3 PRODUCT PORTFOLIO 400
14.11.4 RECENT DEVELOPMENT 400
14.12 CIPLA INC. 401
14.12.1 COMPANY SNAPSHOT 401
14.12.2 REVENUE ANALYSIS 401
14.12.3 PRODUCT PORTFOLIO 402
14.12.4 RECENT DEVELOPMENT 402
14.13 GLENWOOD 403
14.13.1 COMPANY SNAPSHOT 403
14.13.2 PRODUCT PORTFOLIO 403
14.13.3 RECENT DEVELOPMENT 403
14.14 MACLEODS PHARMACEUTICALS LTD. 404
14.14.1 COMPANY SNAPSHOT 404
14.14.2 REVENUE ANALYSIS 404
14.14.3 PRODUCT PORTFOLIO 405
14.14.4 RECENT DEVELOPMENT 405
14.15 ONO PHARMACEUTICAL CO., LTD. 406
14.15.1 COMPANY SNAPSHOT 406
14.15.2 REVENUE ANALYSIS 406
14.15.3 PRODUCT PORTFOLIO 407
14.15.4 RECENT DEVELOPMENT 407
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
